The problem of chronic tonsillitis (CT), its complications and associated diseases with positions of ENT doctor and cardiologist. The etiology and pathogenesis are also presented, as well as chemotherapy and clinical manifestations of conjugate pathology. A modern classification of CT is also presented. We consider the diagnosis of CT and related diseases.

The problem of atherothrombosis and associated diseases is examined here. The estimation of an enteric form of acetylsalicylic acid (a drug Thrombo ASS) from the perspective of evidence-based medicine is also discussed. The use of acetylsalicylic acid in primary and secondary prevention of cardiovascular diseases is demonstrated.

The article briefly describes the inhibitor of angiotensin converting enzyme (ACEI) - fosinopril, calcium channel blocker - diltiazem and antiplatelet agent- acetylsalicylic acid (ASA). The mechanism of their action and possible side effects are given. The authors of the article described in detail the antihypertensive drug from the group ACEI - fosinopril, antiplatelet agent - ASA and non-hydropyridine calcium channel blocker - diltiazem. The results of multicenter randomized trials of ASA, fosinopril in patients with arterial hypertension, ischemic heart disease, nephropathy and heart failure are presented. The article presents a clinical example that demonstrates the selection of the optimal drugs for the treatment of the combined pathology of the heart and kidneys, and also provides an evidence base for the efficacy and safety of fosinopril and ASA preparations. Presented drugs (ASA, fosinopril, diltiazem) are highly effective in all categories of patients with CVD and can be recommended for wider clinical use.

The article presents data from clinical trials that have examined the efficacy and safety of modern calcium antagonist (CA) III generation of lercanidipine. The results of studies show that treatment with lercanidipine leads to a marked reduction in systolic and diastolic blood pressure without significant effect on heart rate. Unique pharmacokinetic characteristics of the drug provide its excellent efficacy and safety, good tolerability, convenience, acceptance and high adherence CA data in patients with hypertension. Additional properties of lercanidipine allow us to recommend the use of the CA in comorbidity.